Corrigendum to ‘EASL recommendations on treatment of hepatitis C: Final update of the series’ [J Hepatol 73 (2020) 1170–1218]

EASL recommendations on treatment of hepatitis C: Final update of the series☆Journal of HepatologyVol. 73Issue 5PreviewHepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. Full-Text PDF It has come to our attention that there was an error in the bibliography in this paper. Reference 354 was incorrectly listed as: Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014; 60: 490-499. Reference 354 should be: Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, et al. Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy. Gastroenterology 2019; 157 (6): 1506-1517. We apologise for any inconvenience caused.